NASDAQ:PHAR

Pharming Group (PHAR) Stock Price, News & Analysis

Pharming Group logo
$11.54 -0.63 (-5.18%)
Closing price 11/20/2026 03:46 PM Eastern
Extended Trading
$11.51 -0.03 (-0.29%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pharming Group Stock (NASDAQ:PHAR)

Advanced

Key Stats

Today's Range
$11.30
▼
$11.97
50-Day Range
$9.11
▼
$13.22
52-Week Range
$9.11
▼
$21.34
Volume
10,505 shs
Average Volume
17,084 shs
Market Capitalization
$816.80 million
P/E Ratio
36.06
Dividend Yield
N/A
Price Target
$39.67
Consensus Rating
Moderate Buy

Company Overview

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system.

Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming also continues to develop medicines for rare diseases.

The company serves patients in the United States, Europe and other markets through its commercial activities and partners. Its products and development programs focus on conditions for which treatment options can be limited.

AI Generated. May Contain Errors.

Pharming Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

PHAR MarketRank™: 
3.79835791817 of 5 stars

Pharming Group scored higher than 76% of companies evaluated by MarketBeat, and ranked 119th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pharming Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Pharming Group has a consensus price target of $39.67, representing about 243.7% upside from its current price of $11.54.

  • Amount of Analyst Coverage

    Pharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pharming Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Pharming Group are expected to grow by 50.00% in the coming year, from $0.34 to $0.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pharming Group is 36.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pharming Group is 36.06, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.45.

  • Price to Book Value per Share Ratio

    Pharming Group has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.04% of the float of Pharming Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Pharming Group has a short interest ratio ("days to cover") of 1.42, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pharming Group has recently increased by 91.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pharming Group does not currently pay a dividend.

  • Dividend Growth

    Pharming Group does not have a long track record of dividend growth.

  • News Sentiment

    Pharming Group has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pharming Group this week, compared to 4 articles on an average week.
  • Search Interest

    4 people have searched for PHAR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Pharming Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pharming Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.07% of the stock of Pharming Group is held by insiders.

  • Percentage Held by Institutions

    0.03% of the stock of Pharming Group is held by institutions.

  • Read more about Pharming Group's insider trading history.
Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHAR Stock News Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Headlines

PHAR Stock Analysis - Frequently Asked Questions

Pharming Group's stock was trading at $17.67 at the beginning of 2026. Since then, PHAR shares have decreased by 34.7% and is now trading at $11.54.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) posted its earnings results on Tuesday, October, 27th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.21 by $0.09. The business had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million. Pharming Group had a net margin of 6.23% and a trailing twelve-month return on equity of 8.70%.
Read the conference call transcript
.

Pharming Group (PHAR) raised $0 in an IPO on Wednesday, December 23rd 2020. The company issued 899,802 shares at $0.00 per share.

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), NVIDIA (NVDA), Plug Power (PLUG), USA Rare Earth (USAR), Advanced Micro Devices (AMD), Verizon Communications (VZ) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
10/27/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PHAR
CIK
1828316
Fax
N/A
Employees
407
Year Founded
1988

Price Target and Rating

High Price Target
$41.00
Low Price Target
$37.00
Potential Upside/Downside
+243.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.32
Trailing P/E Ratio
36.06
Forward P/E Ratio
22.63
P/E Growth
N/A
Net Income
$2.85 million
Net Margins
6.23%
Pretax Margin
8.86%
Return on Equity
8.70%
Return on Assets
4.93%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
3.23
Quick Ratio
2.65

Sales & Book Value

Annual Sales
$376.13 million
Price / Sales
2.17
Cash Flow
$0.18 per share
Price / Cash Flow
62.78
Book Value
$4.11 per share
Price / Book
2.81

Miscellaneous

Outstanding Shares
70,780,000
Free Float
69,313,000
Market Cap
$816.80 million
Optionable
Not Optionable
Beta
-0.05

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:PHAR) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners